Defining lymphocyte‐predominant breast cancer by the proportion of lymphocyte‐rich stroma and its significance in routine histopathological diagnosis

Ohtani, Haruo; Mori‐Shiraishi, Kazuko; Nakajima, M.; Ueki, Hiroyuki

doi:10.1111/pin.12355

Cited by 48 publications

(43 citation statements)

References 25 publications

(46 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Tumors that have more than 50% lymphocytic infiltrate are considered lymphocyte-predominant breast cancer and have the best prognosis [21]. In TNBC, without treatment, the presence of tumor-infiltrating lymphocytes (TILs) is correlated with improved overall survival, increased metastasis-free survival, and decreased distant recurrence [22].…”

Section: Tumor-infiltrating Lymphocytes In Tnbcmentioning

confidence: 99%

Biological Subtypes of Triple-Negative Breast Cancer

2017

View full text Add to dashboard Cite

Triple-negative breast cancers (TNBCs) are defined as tumors that are negative for estrogen, progesterone and HER-2 receptor. At a percentage of 10-20% TNBCs represent a minority in all breast cancers. However, because of the poor prognosis this particular subtype, triple negative disease accounts for a disproportionate number of metastatic cases and breast cancer deaths. Identification of its subtypes is essential for understanding the biological characteristics and clinical behavior of TNBC, as well as for developing personalized treatments. This review will focus on the great progress that has been made in the past few years on identifying new targets in TNBC subtypes and a variety of new treatment options that are on the verge of routine clinical application.

show abstract

Section: Tumor-infiltrating Lymphocytes In Tnbcmentioning

confidence: 99%

Biological Subtypes of Triple-Negative Breast Cancer

2017

View full text Add to dashboard Cite

show abstract

“…In breast cancer, TILs have been reported to vary by subtype. In particular, HER2BC and TNBC have been reported to show signi cantly higher TIL density than HR + HER2 − BC, and TILs have been proven to predict the therapeutic effect of chemotherapy [13,[40][41][42]. Conversely, there are very few reports examining the correlation between TILs and clinicopathological factors or therapeutic effects in HR + HER2 − BC.…”

Section: Discussionmentioning

confidence: 99%

Prediction of Distant Metastatic Recurrence by Tumor-Infiltrating Lymphocytes in Hormone Receptor-Positive Breast Cancer

Takada

Kashiwagi

Asano

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Breast cancer subtypes are known to have different sites of metastatic recurrence. Distant metastases are often seen during the post-operative course in patients with human epidermal growth factor receptor 2 (HER2)-enriched breast cancer (HER2BC) and triple-negative breast cancer (TNBC) while being relatively rare in those with hormone receptor-positive and HER2-negative breast cancer (HR+HER2-BC). Tumor-infiltrating lymphocytes (TILs) can serve as an index to monitor tumor immune microenvironment and possibly predict the prognosis and therapeutic effect in breast cancer. This study aimed to investigate the correlation between TIL density and recurrence site in HR+HER2-BC.Methods: Four-hundred and seventy-one patients with HR+HER2-BC underwent surgery as the first treatment and received adjuvant endocrine therapy except adjuvant chemotherapy at the Osaka City University Hospital from April 2007 to October 2015. To evaluate tumor morphology and examine TILs, needle biopsy specimens were used. Morphological assessment was conducted using conventional hematoxylin and eosin staining.Results: Forty-two patients had a recurrence of breast cancer. In patients with no TIL density, local recurrence was significantly less (p = 0.022), while distant metastases were significantly more (p = 0.015) compared to those in patients with TIL density. Therefore, for the prediction of distant metastases in HR+HER2-BC without chemotherapy, TILs could be used as predictors in univariate analysis (p = 0.015, odds ratio [OR] = 0.127), although not as independent factors (p = 0.285, OR = 0.144).Conclusions: We concluded that TILs may be able to predict distant metastatic recurrence in stages I–II of HR+HER2-BC.

show abstract

“…It should be noted that in the latest (fourth) edition WHO classification of tumours of the breast, both MC and AMC are collectively termed as carcinoma with medullary features [55]. Lymphocyte-rich invasive breast carcinoma or LPBC is defined as a carcinoma with at least 50-60% inflammatory stroma [56]. The distinction between LELC-B and LPBC lies in the amount of the lymphocytic infiltrate, which in LPBC should not be as intense as in LELC-B, thereby obscuring the neoplastic cells.…”

Section: Discussionmentioning

confidence: 99%

Lymphoepithelioma-like breast carcinoma

Koufopoulos¹,

Syrios²,

Papanikolaou³

et al. 2018

pjp

View full text Add to dashboard Cite

Nasopharyngeal lymphoepithelioma is an undifferentiated carcinoma in a dominated lymphoplasma-histiocyte stroma. Lymphoepithelioma-like carcinoma of the breast is the mammary counterpart of the lymphoepithelioma of the nasopharynx and is characterised by proliferation of poorly differentiated malignant cells within a prominent lymphoid infiltrate. It is a very rare primary carcinoma of the breast first reported in 1994 by Kumar and Kumar. Fewer than 40 cases have been reported in the English literature. In this manuscript a case of lymphoepithelioma-like carcinoma of the breast in a 57-year-old patient is reported along with a literature review on this rare entity.

show abstract

Defining lymphocyte‐predominant breast cancer by the proportion of lymphocyte‐rich stroma and its significance in routine histopathological diagnosis

Cited by 48 publications

References 25 publications

Biological Subtypes of Triple-Negative Breast Cancer

Biological Subtypes of Triple-Negative Breast Cancer

Prediction of Distant Metastatic Recurrence by Tumor-Infiltrating Lymphocytes in Hormone Receptor-Positive Breast Cancer

Lymphoepithelioma-like breast carcinoma

Contact Info

Product

Resources

About